Results 141 to 150 of about 1,494 (190)

Clinico-hematopathologic and Genetic Characteristics of Korean Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Single-Center Cohort Study. [PDF]

Ann Lab Med
Kim J, Kim M, Chu D, Cho YU, Hwang SH, Jang S, Seo EJ, Choi EJ, Park HS, Lee JH, Lee JH, Yoon DH, Go H, Park CS, Lee KH, Park CJ, Hwang S.   +16 more
europepmc   +1 more source

Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax. [PDF]

Ann Hematol
Zhang M, Chai X, Zhang X, Lu W, Lyu H, Pu Y, Meng J, Lyu C, Zhao M.   +8 more
europepmc   +1 more source

First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial. [PDF]

Br J Haematol
Stein AS, Lane AA, Sweet KL, Vasu S, Tosolini A, Katsetos J, Konopleva M, Pemmaraju N.   +7 more
europepmc   +1 more source

A case of blastic plasmacytoid dendritic cell neoplasm in a young male with atypical cutaneous findings. [PDF]

JAAD Case Rep
Sonuga O, Patel AB, Brady BH, Doan L, Smith J.   +4 more
europepmc   +1 more source

Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives. [PDF]

Biochem Med (Zagreb)
de Almeida GB, Dos Santos MM, de Oliveira Barbosa D, Conceição RR, de Almeida Lopes B, de Melo Santos HH, Marchioro SB.   +6 more
europepmc   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Series and Review of Literature. [PDF]

Cureus
Staessens S, De Beule N, Trullemans F, De Becker A.   +3 more
europepmc   +1 more source

Imaging findings for 2-[¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in blastic plasmacytoid dendritic cell neoplasm: case series and literature review. [PDF]

Front Med (Lausanne)
Zhou Y, Li K, Jin X, Yuan L, Zhou H, Li X.   +5 more
europepmc   +1 more source

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

Cancers, 2022
No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chemotherapy followed by hematopoietic stem cell transplantation remains an effective treatment. However, relapses frequently occur with the development of resistance.
Eric Deconinck, Margaux Poussard, Fanny Angelot-Delettre   +2 more
exaly   +4 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

Current Hematologic Malignancy Reports, 2018
Engagement on social media for professional, healthcare-related communication is rapidly rising around the world. We aimed to better understand the dynamics of a rare disease Twitter hashtag community.Twitter has served as a platform for academic discussion, a method for knowledge dissemination directly from medical meetings, and a venue for patient ...
Andrew A Lane, Vikas Gupta, Naveen Pemmaraju   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Targeting CD123 in BPDCN: an emerging field

Expert Review of Hematology, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with historically poor outcomes for patients, often refractory to traditional chemotherapy. Recent research has focused on targeted therapy to improve responses and limit potential toxicity.CD123 (also known as IL-3 Rα) is a cell surface marker and ...
Naveen Pemmaraju, Adam J DiPippo, Nathaniel R Wilson   +2 more
exaly   +3 more sources